Concord Drugs reports Rs 2.2079 crore half-year September PAT

Concord Drugs Limited reported standalone profit after tax of Rs 2.2079 crore for the six months ended September 30, 2026, from total revenue of Rs 41.6423 crore. Profit before tax was Rs 3.0465 crore and total expenses were Rs 38.5957 crore, according to the unaudited results approved on November 12, 2026.

What did Concord Drugs report for the September 2026 half-year?

Concord Drugs reported standalone profit after tax, or PAT, of Rs 2.2079 crore for the six months ended September 30, 2026. The board approved the unaudited standalone and consolidated results on November 12, 2026, and took note of the statutory auditor's limited review report under the Securities and Exchange Board of India listing regulations.

Standalone profit before tax, or PBT, was Rs 3.0465 crore, with no exceptional item shown in the statement. The company recorded a current-tax charge of Rs 0.8560 crore and a deferred-tax credit of Rs 0.0174 crore, producing a total tax expense of Rs 0.8386 crore and the reported PAT of Rs 2.2079 crore.

How did Concord Drugs' half-year revenue compare with the prior year?

Concord Drugs generated Rs 41.5779 crore of revenue from operations in the six months ended September 30, 2026, while other income was Rs 0.0643 crore. Operations therefore accounted for nearly all of the Rs 41.6423 crore of total revenue reported for the period, rather than income outside the main business.

The filing gives Rs 75.8486 crore of revenue from operations and Rs 75.8830 crore of total revenue for the year ended March 31, 2026. This is a 12-month comparator against the September 2026 six-month period, so the two periods show reported scale but do not establish a like-for-like half-year change.

Other income increased to Rs 0.0643 crore in the September 2026 half-year from Rs 0.0344 crore in the year ended March 2026. The difference between total revenue and operating revenue remained limited in both reported periods, at Rs 0.0643 crore and Rs 0.0344 crore respectively.

What costs produced Concord Drugs' Rs 3.0465 crore pre-tax profit?

Concord Drugs reported total standalone expenses of Rs 38.5957 crore for the six months ended September 30, 2026, against total revenue of Rs 41.6423 crore. That left PBT of Rs 3.0465 crore, compared with Rs 1.4486 crore of PBT on Rs 75.8830 crore of revenue for the year ended March 31, 2026.

Cost of materials consumed was the largest named expense at Rs 33.5686 crore during the half-year. The statement also recorded Rs 2.8021 crore of employee-benefit expense, Rs 0.8662 crore of finance costs, Rs 0.7036 crore of depreciation and amortisation expense, and Rs 0.9105 crore of other expenses.

The full-year March 2026 statement reported Rs 63.4453 crore of material consumption, Rs 4.8991 crore of employee-benefit expense and Rs 1.4591 crore of finance costs. Its total expenses of Rs 74.4344 crore were Rs 1.4486 crore below its total revenue, which was the amount reported as PBT because no exceptional item was shown.

How close were Concord Drugs' consolidated and standalone results?

Concord Drugs reported consolidated PAT of Rs 2.2114 crore for the six months ended September 30, 2026, compared with standalone PAT of Rs 2.2079 crore. Consolidated total revenue was Rs 41.7565 crore, Rs 0.1142 crore above the standalone total of Rs 41.6423 crore.

Consolidated PBT was Rs 3.0512 crore, compared with standalone PBT of Rs 3.0465 crore. Consolidated tax expense was Rs 0.8400 crore, versus standalone tax expense of Rs 0.8386 crore, and the filing does not separately explain the difference between the two reporting bases.

Standalone basic and diluted earnings per share were both Rs 1.98 for the six months ended September 30, 2026, compared with Rs 0.93 for the year ended March 31, 2026. Paid-up equity share capital was Rs 13.1750 crore at September 30, 2026, with a face value of Rs 10 per share; the filing states that interim earnings per share are not annualised.

What changed in Concord Drugs' balance sheet and cash flow?

Concord Drugs' standalone total assets were Rs 94.3082 crore at September 30, 2026, compared with Rs 71.8548 crore at March 31, 2026. Current assets increased to Rs 70.7111 crore from Rs 49.4738 crore, while trade receivables rose to Rs 44.3229 crore from Rs 28.1288 crore and inventory declined to Rs 17.1729 crore from Rs 18.3499 crore.

Total equity was Rs 50.7218 crore at September 30, 2026, up from Rs 48.5139 crore at March 31, 2026. Current liabilities were Rs 35.0805 crore against Rs 18.0240 crore, including Rs 17.8179 crore of trade payables and Rs 15.2278 crore of current borrowings at the September balance-sheet date.

Standalone net cash flow from operating activities was an outflow of Rs 7.4854 crore for the six months ended September 30, 2026. The filing recorded a Rs 16.1941 crore increase in trade receivables and a Rs 11.7961 crore increase in trade payables within working-capital movements, while cash and cash equivalents ended the period at Rs 0.2718 crore.

Net financing cash flow was Rs 7.8702 crore in the September 2026 half-year, compared with Rs 8.6544 crore for the year ended March 31, 2026. The reported financing movement included Rs 5.5333 crore of government grants and Rs 3.2031 crore relating to repayment of short-term borrowings, while finance costs paid were Rs 0.8662 crore.

Conclusion

Concord Drugs' September 2026 half-year filing shows Rs 2.2079 crore of standalone PAT on Rs 41.6423 crore of revenue, with Rs 3.0465 crore of PBT before a Rs 0.8386 crore tax expense. The consolidated PAT of Rs 2.2114 crore was close to the standalone result, while receivables of Rs 44.3229 crore were a major component of the Rs 70.7111 crore current-asset balance.

The company said the results will be published in newspapers and made available on its investor-relations website and the BSE website following the November 12, 2026 board meeting. Subsequent filings will show whether the Rs 44.3229 crore receivables balance, Rs 17.8179 crore trade payables and Rs 7.4854 crore operating cash outflow change after the September 2026 half-year.